CHDI Foundation Revenue and Competitors

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • CHDI Foundation's estimated annual revenue is currently $23.1M per year.(i)
  • CHDI Foundation's estimated revenue per employee is $201,000

Employee Data

  • CHDI Foundation has 115 Employees.(i)
  • CHDI Foundation grew their employee count by 1% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$12.3M617%N/AN/A
#2
$354.3M461-2%$567.1MN/A
#3
$377.1M1876-1%N/AN/A
#4
$7.8M398%N/AN/A
#5
$5.4M270%N/AN/A
#6
$45M2246%N/AN/A
#7
$6.8M34-82%N/AN/A
#8
$9.2M4612%N/AN/A
#9
N/A69446%N/AN/A
#10
$15.5M775%N/AN/A
Add Company

"Rapidly discover and develop drugs that delay or slow Huntington's disease". CHDI's goal is to increase the understanding of Huntington's disease (HD) and to hasten the development of therapies. We collaborate with academic and industrial scientists throughout the world.

keywords:Biotechnology,Healthcare,Pharmaceuticals

N/A

Total Funding

115

Number of Employees

$23.1M

Revenue (est)

1%

Employee Growth %

N/A

Valuation

N/A

Accelerator

CHDI Foundation's People

NameTitleEmail/Phone
1
Director, In Vivo PharmacologyReveal Email/Phone
2
Director, RNA BiologyReveal Email/Phone
3
Director, Stem Cell Biology & Regenerative MedicineReveal Email/Phone
4
Director InformaticsReveal Email/Phone
5
Clinical Research Program ManagerReveal Email/Phone
6
Clinical Program ManagerReveal Email/Phone
7
Clinical Program ManagerReveal Email/Phone
8
Program Manager, Biorepositories and Research ToolsReveal Email/Phone
9
Chief Legal OfficerReveal Email/Phone
10
Director, Molecular Systems BiologyReveal Email/Phone

CHDI Foundation News

2022-04-20 - Driving Forward Huntington's Disease Research

CL: The CHDI foundation is a privately funded, not-for-profit biomedical research organization whose main mission is devoted to developing drugs...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$7.5M1157%N/A
#2
$15M115-9%N/A
#3
$37.1M1153%N/A
#4
$15M1151%N/A
#5
$28.9M1152%N/A